Life Sciences Review Magazine
Mar 31, 2026
Advancing Drug Discovery Journey with Inference AI Driven Confidence
Excited to share that Proholistic Discovery has been recognized by Life Sciences Review as a Top ADMET Prediction & PKPD Modeling Solution in Canada (2026).
In drug development, nearly 90% of candidates fail, with ~45% linked to ADMET and PK challenges . The core issue isn’t a lack of models—but the inability to reconcile conflicting predictions.
Our approach:
➡️ An Inference AI platform that integrates outputs from multiple tools
➡️ Resolves uncertainty into probability-weighted, actionable insights
➡️ Enables smarter candidate selection and more confident clinical decisions
Proud of the team and partners who made this possible—and excited about what’s next as we continue building toward more predictive, human-relevant drug development.
🔗 Read the full feature: www.lifesciencesreview.com/proholistic-discovery-2026